Achilles Therapeutics (ACHL)
(Delayed Data from NSDQ)
$0.76 USD
-0.01 (-1.86%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.75 -0.01 (-1.32%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ACHL 0.76 -0.01(-1.86%)
Will ACHL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACHL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACHL
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
ACHL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development
Other News for ACHL
Piper downgrades Achilles to neutral, cites latest data
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
BRNS, UPC and KWE among mid-day movers
IN BRIEF: Syncona notes investee Achilles's annual loss narrows
Achilles Therapeutics GAAP EPS of -$0.46 misses by $0.32